Device Trial Radar · NCT02394379
Post Approval Study to Evaluate the Trulign™ Toric Posterior Chamber IOL
Last checked: Nov 20, 2026Latest source record: Nov 13, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
600
Planned (sponsor's estimate)
Start
Mar 19, 2015
Primary completion
Aug 5, 2019
Study completion Aug 5, 2019
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Bausch Health Americas, Inc.
- First posted
- Mar 20, 2015
Design
- Study type
- Observational
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the incidence of IOL vaulting (ie, position change) of the Trulign™ Toric IOL following cataract surgery.
Conditions
- Cataract
Interventions
Trulign™ Toric IOLDevice
Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of clinically significant IOL vaultingTime frame: Up to 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bausch & Lomb Incorporated
Rochester, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.